purine

01/01/2011 - "The results indicate that the introduction of a methyl group in the purine 2-position is beneficial for antimycobacterial and antiprotozoal activity, and that amino groups may enhance activity against several cancer cell lines."
12/01/2020 - "In this study we investigated the apoptotic mechanism and the anti-cancer effects of a novel purine-based PPARγ agonist, CB11 (8-(2-aminophenyl)-3-butyl-1,6,7-trimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione), on human NSCLC cells. "
01/01/2017 - "The structure-activity relationship studies reported that the substitution at C-6 positions in purine nucleus with the 4-phenoxyphenyl group is responsible for the anti-cancer activity."
01/01/2016 - "The purpose of this study was to recognize the expanded purine repeats (EPRs) in human genome and find their correlation with cancer pathogenesis. "
04/21/2005 - "The study identifies derivative 11v as the most potent Hsp90 inhibitor of the purine-scaffold series published to date (EC(50) = 30 nM), and also as the compound of this class with highest selectivity for tumor vs normal cell Hsp90 (700 to 3000-fold). "

05/01/2014 - "Abstract Purine analogs are highly effective in hairy cell leukemia (HCL) with response rates of 85%, but with many late relapses. "
12/01/2004 - "Purine analogues have dramatically improved the outcome of patients affected by hairy cell leukemia (HCL), although complete eradication of disease was achieved in few cases. "
02/01/2023 - "In classical hairy cell leukemia (HCL), standard treatments including purine analogs achieve a durable response (up to 90%), but lead to severe immunosuppression and long-lasting depletion of CD4 + T lymphocytes. "
12/14/2021 - "Hairy cell leukemia variant (HCLv) responds poorly to purine analogue monotherapy. "
10/01/2021 - "Hairy cell leukemia (HCL) responds well to purine analogs with an overall median relapse free survival of 11-16 years. "

07/01/2003 - "Therapeutic results in advanced chronic lymphocytic leukemia (CLL) are still unsatisfactory in terms of complete remission achievement and duration, in spite of the extensive use of purine analogs. "
03/01/2012 - "Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials."
01/01/2018 - "Patients with residual chronic lymphocytic leukemia (CLL) following initial purine analog-based chemoimmunotherapy exhibit a shorter duration of response and may benefit from novel therapeutic strategies. "
10/15/2016 - "TP53 abnormalities lead to resistance to purine analogues and are found in over 40% of patients with refractory chronic lymphocytic leukemia (CLL). "
06/21/2016 - "Purine analogs are among the most effective chemotherapeutic drugs for the treatment of chronic lymphocytic leukemia (CLL). "

11/01/1989 - "[Clearance of oxypurines in normal subjects and in gout patients subjected to a purine-free diet. "
09/01/2012 - "The study findings suggest that acute purine intake increases the risk of recurrent gout attacks by almost fivefold among gout patients. "
01/01/1958 - "[Excretion of purine bodies in urine in subjects of gout; chromatographic and spectrophotometric study]."
11/01/2023 - "A liquid chromatography-tandem mass spectrometry method for comprehensive determination of metabolites in the purine pathway of rat plasma and its application in anti-gout effects of Lycium ruthenicum Murr."
10/01/2023 - "Beyond classical gout, there are also gouts in connection with purine metabolism disorders known as "enzymopathic gouts". "

12/01/1983 - "In studies with the human promyelocytic leukemia cell line HL-60, we defined changes in intermediary purine metabolism that appear to contribute to the regulation of terminal maturation in myeloid cells. "
01/01/2022 - "Targeting leukemia-specific dependence on the de novo purine synthesis pathway."
01/01/2021 - "Among the tested compounds, 6-morpholino 17 and 6-amino 22 derivatives, with trans-β-styrenesulfonyl group attached at the N9 position of purine, proved to be the most effective antiproliferative agents, causing accumulation of leukemia cells in subG0 cell cycle phase."
01/01/2020 - "New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia."
10/19/2016 - "Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia."